---
freshness:
  last-reviewed: 2026-02-05
  data-year: 2026
  review-cycle: 12
  sections:
    - name: "Legislation Evaluations"
      data-year: 2026
    - name: "Engagement Consistency Assessment"
      data-year: 2026
notes:
  - Revisit after any exercise of march-in rights or major court ruling on Bayh-Dole.
  - Flag changes to NIST march-in framework rulemaking for reassessment.
  - Update after SBIR/STTR reauthorization votes to reflect changed positions.
sources:
  count: 0
  verified: 2026-02-05
  broken: 0
---

# Technology Transfer: Political Perspectives Analysis

## Overview

This document analyzes technology transfer policy through nine distinct political perspectives, evaluating current state assessments, root cause analyses, proposed solutions, and legislation. Each perspective receives engagement consistency ratings and position scores, culminating in compromise proposals that bridge multiple viewpoints. Technology transfer occupies an unusual political space: it involves both intellectual property rights (which the right generally champions) and public return on taxpayer investment (which the left generally champions), creating cross-cutting alignments that defy simple left-right categorization.

## Perspective Definitions

| Perspective | Core Values | Policy Orientation |
|-------------|-------------|-------------------|
| Conservative | Tradition, limited government, individual responsibility | Incremental change, fiscal restraint, market solutions |
| Liberal | Progress, equality, social responsibility | Government as problem-solver, regulation, safety nets |
| Progressive | Systemic change, economic justice, structural reform | Transformative reform, wealth redistribution, worker power |
| Libertarian | Individual liberty, minimal state, free markets | Deregulation, privatization, voluntary association |
| Constitutionalist | Original intent, enumerated powers, federalism | Strict constitutional limits, states' rights |
| Populist | Anti-elite, pro-worker, economic nationalism | Trade protection, anti-monopoly, immigration restriction |
| Centrist | Pragmatism, compromise, incremental progress | Bipartisan solutions, evidence-based policy |
| Religious Right | Faith-based values, traditional morality | Social conservatism, religious liberty |
| Democratic Socialist | Worker ownership, public goods, democratic control | Public investment, labor rights, universal programs |

## Scoring Framework

### Position Scores (1-10)

| Score | Meaning |
|-------|---------|
| 10 | Full agreement with project analysis |
| 7-9 | Substantial to strong agreement |
| 5-6 | Mixed/moderate agreement |
| 3-4 | Substantial disagreement |
| 1-2 | Strong opposition |

### Engagement Consistency (1-5)

This metric assesses how reliably a perspective's stated positions align with its underlying principles, and how stable those positions are when concerns are addressed. Higher scores indicate more predictable negotiating partners.

| Level | Label | Indicators |
|-------|-------|------------|
| 5 | Highly Consistent | Stated positions reflect underlying principles; positions stable when concerns addressed |
| 4 | Mostly Consistent | Principles generally align with positions; minor strategic flexibility |
| 3 | Mixed Consistency | Some positions principled, others reflect coalition pressures or unstated concerns |
| 2 | Low Consistency | Positions shift frequently; stated concerns differ from underlying priorities |
| 1 | Unpredictable | Positions appear driven primarily by opposition dynamics rather than principles |

**Coalition-Building Considerations:**

- Alignment gap: When stated concerns differ from underlying priorities, addressing stated concerns may not secure support
- Position stability: Perspectives with shifting positions require ongoing negotiation
- Principle consistency: Perspectives that apply principles uniformly are more predictable partners
- Internal diversity: Some perspectives contain factions with different priorities

### Legislation Status Reference (as of 2026-02-05)

| Bill/Amendment | Type | Current Status | Last Action |
|----------------|------|----------------|-------------|
| *Publicly Funded Research Accountability Act* | *Federal* | *Proposed* | *Draft legislation* |
| *Innovation Commercialization and Regional Equity Act* | *Federal* | *Proposed* | *Draft legislation* |

*Note: Status reflects proposed legislation in this analysis. See [11-legislation.md](11-legislation.md) for full bill text.*

---

## Perspective Analyses

### Conservative Perspective

#### Engagement Consistency Assessment

**Score: 3/5 - Mixed Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | *Stated concern is protecting innovation and IP rights; underlying priority often includes protecting pharmaceutical industry donors and allies* |
| Principle consistency | *Strong IP protection is consistent with property rights principles, but tolerance for government-granted monopolies that charge unlimited prices is in tension with free-market principles* |
| Goalpost stability | *Moderate; tends to shift from "march-in was never intended for pricing" to "any government intervention destroys innovation" depending on the argument needed* |
| Zero-sum behavior | *Some; tends to frame any march-in reform as total destruction of IP rather than calibrated adjustment* |

**Justification:** Conservatives hold genuine commitments to property rights and market freedom, but these principles are inconsistently applied when government-granted patent monopolies are at issue. The tension between free-market principles and defense of government-enabled monopoly pricing reduces consistency.

**Evidence for assessment:**

- *Heritage Foundation and AEI publications defending Bayh-Dole status quo while simultaneously criticizing government market distortions in other contexts*
- *Republican support for SBIR/STTR programs (government subsidy to business) while opposing other forms of industrial policy*
- *Conservative members of Congress accepting pharmaceutical industry campaign contributions while opposing drug pricing reform*

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 5/10 | *Agree that the system has produced innovation but disagree that pricing or access problems are significant enough to warrant intervention* |
| Root Cause Agreement | 4/10 | *Reject the framing that march-in failure or TTO revenue maximization are problems; attribute commercialization gaps to insufficient private-sector incentives* |

**Source references:**

- *Heritage Foundation. "Bayh-Dole Works: Hands Off March-In Rights." Backgrounder, 2023*
- *AEI. "The Case for Strong Patent Protections in University Research." Policy paper, 2022*

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| *Activate march-in rights* | 2/10 | *"March-in was never intended for price control and would destroy innovation incentives"* | *Protecting pharmaceutical industry allies; preserving IP value system that benefits major donors* |
| *Strengthen Bayh-Dole accountability* | 3/10 | *"Additional reporting burdens would stifle university innovation"* | *Concerns about government overreach and precedent for broader regulation* |
| *Reform TTO incentives* | 5/10 | *"Market-driven TTOs are efficient; government metrics would politicize decisions"* | *Genuine belief in market efficiency, but also resistance to public interest mandates* |
| *Bridge the valley of death* | 6/10 | *"Private capital should fill this gap, but targeted programs can help"* | *Supportive of programs benefiting business, wary of expanding government role* |
| *Modernize lab tech transfer* | 7/10 | *"Government labs should operate more like the private sector"* | *Genuine support for reducing bureaucracy; aligns with deregulatory principles* |
| *Strengthen SBIR/STTR* | 6/10 | *"Small business programs are valuable but should focus on merit"* | *Supportive of business subsidies; wary of geographic equity mandates as social engineering* |
| *Ensure public return on drugs* | 2/10 | *"Price controls would devastate pharmaceutical R&D"* | *Industry alignment; ideological opposition to government pricing role* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| *Publicly Funded Research Accountability Act* | 2/10 | *"This is backdoor price control that would chill innovation"* | *Fundamental opposition to government role in pricing; industry alignment* |
| *Innovation Commercialization and Regional Equity Act* | 5/10 | *"The commercialization elements are good, but geographic mandates are problematic"* | *Supports business-friendly provisions; opposes equity-oriented redistribution* |

#### Alternative Proposals

- Strengthen patent protections and extend exclusivity periods to incentivize development of publicly funded inventions
- Reduce regulatory barriers to commercialization rather than adding new government programs
- Expand tax incentives for companies that license and develop university inventions
- Promote voluntary industry commitments to patient access programs rather than mandatory pricing provisions

#### Coalition Potential

- **Natural allies:** Libertarian (on IP rights and deregulation), Religious Right (on limited government)
- **Potential bridges:** Centrist (on commercialization programs), Populist (on regional innovation)
- **Unlikely partners:** Progressive, Democratic Socialist (fundamental disagreement on pricing and public interest)

---

### Liberal Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | *Genuinely concerned about public access and return on investment; positions align well with stated values* |
| Principle consistency | *Generally consistent application of "public investment should yield public benefit" principle* |
| Goalpost stability | *Stable; has maintained consistent position on march-in rights and drug pricing for decades* |
| Zero-sum behavior | *Low; generally willing to accept compromise that achieves meaningful reform even if imperfect* |

**Justification:** Liberals have maintained a consistent position that publicly funded research should yield public benefits, including affordable access to resulting products. This consistency makes them reliable coalition partners on technology transfer reform.

**Evidence for assessment:**

- *Democratic platform consistently supporting drug pricing reform and public access to research*
- *Liberal think tanks (Center for American Progress, Brookings) producing sustained analysis of technology transfer reform*
- *Congressional Democrats introducing march-in legislation across multiple sessions*

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 8/10 | *Strong agreement that the system has produced innovation but failed on access, pricing, and equity* |
| Root Cause Agreement | 7/10 | *Agree with most root cause analysis; may place somewhat less emphasis on TTO culture and more on industry capture* |

**Source references:**

- *Center for American Progress. "Putting the Public Back in Publicly Funded Research." Policy report, 2023*
- *Brookings Institution. "Reforming Technology Transfer for the 21st Century." Hamilton Project paper, 2022*

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| *Activate march-in rights* | 8/10 | *"March-in should be exercised when publicly funded drugs are priced beyond reach"* | *Genuine concern about access; also a politically popular position* |
| *Strengthen Bayh-Dole accountability* | 8/10 | *"Transparency and accountability for public investment are essential"* | *Consistent with good-government principles* |
| *Reform TTO incentives* | 7/10 | *"TTOs should prioritize public benefit alongside revenue"* | *Supportive but cautious about disrupting university systems* |
| *Bridge the valley of death* | 8/10 | *"Public investment in commercialization infrastructure is appropriate"* | *Consistent with government's role in market failures* |
| *Modernize lab tech transfer* | 7/10 | *"Labs should be more effective at getting research to market"* | *Supportive of efficiency; cautious about privatization* |
| *Strengthen SBIR/STTR* | 8/10 | *"Programs should be reformed to reach more diverse businesses and regions"* | *Strong support for equity and geographic distribution* |
| *Ensure public return on drugs* | 8/10 | *"Taxpayers who fund research should benefit from affordable products"* | *Core principle of public accountability* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| *Publicly Funded Research Accountability Act* | 8/10 | *"Overdue reform that brings accountability to publicly funded research"* | *Strong support; may push for stronger pricing provisions* |
| *Innovation Commercialization and Regional Equity Act* | 8/10 | *"Important investment in innovation infrastructure and equity"* | *Strong support for both commercialization and equity provisions* |

#### Alternative Proposals

- Go further on pricing: mandatory reasonable pricing provisions in all licenses, not just exclusive ones
- Expand the public database to include all federal research outputs, not just Bayh-Dole inventions
- Create a public-option pharmaceutical manufacturer for essential drugs developed with public funding
- Require HBCUs and minority-serving institutions to be prioritized in technology transfer support

#### Coalition Potential

- **Natural allies:** Progressive, Democratic Socialist (on pricing and public access)
- **Potential bridges:** Centrist (on evidence-based reform), Populist (on anti-corporate pricing)
- **Unlikely partners:** Conservative, Libertarian (on government pricing role)

---

### Progressive Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | *Genuinely motivated by systemic reform to ensure public benefit from public investment* |
| Principle consistency | *Highly consistent application of "public goods should serve the public" principle* |
| Goalpost stability | *Stable on core demands but willing to escalate if initial reforms prove insufficient* |
| Zero-sum behavior | *Some; may resist incremental reforms as insufficient, preferring comprehensive restructuring* |

**Justification:** Progressives have the most coherent ideological framework on this issue: public investment should yield public benefit, period. Their consistency is strong, though their preference for comprehensive reform over incrementalism can create coalition difficulties.

**Evidence for assessment:**

- *Senator Sanders and progressive caucus members consistently introducing legislation on march-in rights and drug pricing*
- *Progressive think tanks and advocacy organizations maintaining sustained campaigns on publicly funded research accountability*
- *Academic progressives publishing research documenting public funding behind commercial drugs*

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 9/10 | *Strong agreement with the analysis of system failures, with emphasis on corporate capture and inequity* |
| Root Cause Agreement | 9/10 | *Close alignment on structural causes, particularly industry influence, revenue-maximizing TTO culture, and geographic concentration* |

**Source references:**

- *Knowledge Ecology International. Extensive filings and analysis on march-in rights. Various dates*
- *Public Citizen. "Exposed: How Federal Tax Dollars Fund the Drug Companies." Report, 2021*

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| *Activate march-in rights* | 9/10 | *"March-in should be used aggressively to bring drug prices down"* | *Central demand; viewed as test of political will* |
| *Strengthen Bayh-Dole accountability* | 8/10 | *"Necessary but not sufficient without pricing enforcement"* | *Supports transparency as a step toward systemic reform* |
| *Reform TTO incentives* | 7/10 | *"TTOs should serve the public, not institutional revenue"* | *Supportive but sees this as secondary to pricing and access reform* |
| *Bridge the valley of death* | 7/10 | *"Public investment is good but should come with public ownership stakes"* | *Wants public equity or ownership, not just grants* |
| *Modernize lab tech transfer* | 6/10 | *"Labs should transfer technology but not give away public assets to corporations"* | *Cautious about privatization of public research* |
| *Strengthen SBIR/STTR* | 7/10 | *"Programs need reform but are fundamentally corporate subsidies"* | *Prefers public enterprise to small business subsidies for some applications* |
| *Ensure public return on drugs* | 10/10 | *"The public should own or control the products of publicly funded research"* | *Core principle; may push beyond the proposed legislation* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| *Publicly Funded Research Accountability Act* | 7/10 | *"A good start but should go further on pricing and public ownership"* | *Would push for mandatory pricing provisions and government manufacturing option* |
| *Innovation Commercialization and Regional Equity Act* | 7/10 | *"Useful but insufficient without structural reform of who benefits from public research"* | *Wants stronger equity provisions and public ownership stakes* |

#### Alternative Proposals

- Establish a public pharmaceutical manufacturer for drugs developed with public funding
- Require public equity stakes in companies commercializing publicly funded inventions
- Default to non-exclusive licensing for all publicly funded inventions unless exclusive licensing is specifically justified
- Create a public venture fund that invests in commercialization and returns profits to the public

#### Coalition Potential

- **Natural allies:** Democratic Socialist (on public ownership), Liberal (on access and pricing)
- **Potential bridges:** Populist (on anti-corporate sentiment), Centrist (on specific reform elements)
- **Unlikely partners:** Conservative, Libertarian, Religious Right (fundamental disagreement on government role)

---

### Libertarian Perspective

#### Engagement Consistency Assessment

**Score: 3/5 - Mixed Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | *Genuine commitment to property rights and free markets, but inconsistently applied to government-granted monopolies* |
| Principle consistency | *Principled opposition to government intervention should logically extend to opposition to government-granted patent monopolies, but often does not* |
| Goalpost stability | *Moderate; position depends on which libertarian principle is prioritized (property rights vs. free markets vs. anti-monopoly)* |
| Zero-sum behavior | *Low; generally willing to engage with specific proposals on their merits* |

**Justification:** Libertarians face a genuine philosophical tension on this issue: strong property rights principles support patent protection, but anti-monopoly and free-market principles argue against government-enabled monopoly pricing. Different libertarian thinkers resolve this tension differently, reducing overall consistency.

**Evidence for assessment:**

- *Cato Institute publishing both pro-patent and anti-patent scholarship*
- *Libertarian economists (e.g., Alex Tabarrok) arguing against patent monopolies on free-market grounds*
- *Reason Foundation supporting Bayh-Dole while criticizing pharmaceutical monopoly pricing*

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 5/10 | *Agree that the system produces distortions but attribute them to government intervention rather than insufficient intervention* |
| Root Cause Agreement | 4/10 | *See the root cause as government involvement in innovation (patents, grants, regulation) rather than insufficient accountability* |

**Source references:**

- *Cato Institute. "Rethinking the Patent System." Policy Analysis, various dates*
- *Tabarrok, Alex. "Patent Theory versus Patent Law." Contributions to Economic Analysis and Policy, 2002*

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| *Activate march-in rights* | 3/10 | *"Government should not retroactively change the terms of patent rights"* | *Property rights absolutism; but some libertarians see march-in as correcting a government distortion* |
| *Strengthen Bayh-Dole accountability* | 3/10 | *"More reporting means more bureaucracy and less innovation"* | *Anti-regulatory instinct* |
| *Reform TTO incentives* | 4/10 | *"Markets, not government metrics, should drive TTO behavior"* | *Opposition to government-directed institutional reform* |
| *Bridge the valley of death* | 3/10 | *"Government should not pick winners; private capital is more efficient"* | *Opposition to government subsidies for commercialization* |
| *Modernize lab tech transfer* | 5/10 | *"If government labs must exist, they should operate more efficiently"* | *Accepts reform but would prefer to privatize or close labs* |
| *Strengthen SBIR/STTR* | 3/10 | *"SBIR is a government subsidy that distorts private markets"* | *Principled opposition to government subsidies; would prefer tax cuts* |
| *Ensure public return on drugs* | 2/10 | *"Government should not set drug prices; deregulate to increase competition instead"* | *Anti-price control; but some libertarians support march-in as correcting a government monopoly* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| *Publicly Funded Research Accountability Act* | 2/10 | *"Expands government authority over private property and markets"* | *Opposition to government pricing authority; concern about regulatory expansion* |
| *Innovation Commercialization and Regional Equity Act* | 3/10 | *"Government should not subsidize commercialization or engineer geographic outcomes"* | *Opposition to subsidies and geographic mandates* |

#### Alternative Proposals

- Reduce patent terms and scope to increase market competition rather than using march-in
- Deregulate FDA approval processes to enable faster, cheaper drug development
- Eliminate SBIR/STTR and replace with broad-based R&D tax credits
- Privatize national laboratories or convert them to independent research institutes
- Reduce government funding of research and allow private markets to direct innovation

#### Coalition Potential

- **Natural allies:** Conservative (on property rights and deregulation)
- **Potential bridges:** Populist (on anti-monopoly positions), Progressive (on patent reform specifically)
- **Unlikely partners:** Liberal, Democratic Socialist (on government's role in pricing and markets)

---

### Constitutionalist Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | *Genuine commitment to constitutional limits and enumerated powers* |
| Principle consistency | *Generally consistent; the Patent Clause (Art. I, Sec. 8, Cl. 8) provides clear constitutional basis for this policy area* |
| Goalpost stability | *Stable; positions grounded in constitutional text are relatively fixed* |
| Zero-sum behavior | *Low; willing to support constitutionally grounded reforms* |

**Justification:** Constitutionalists have a relatively clear framework on this issue. The Patent Clause expressly grants Congress power "to promote the Progress of Science and useful Arts," establishing a constitutional basis for both patent grants and conditions on those grants. This provides a stable foundation for policy positions.

**Evidence for assessment:**

- *Federalist Society scholarship on the Patent Clause and its purposes*
- *Conservative legal scholars acknowledging congressional authority to condition patent rights on public benefit*
- *Originalist analysis supporting the view that patents were always understood as conditional grants, not absolute rights*

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 5/10 | *Accept factual descriptions but frame issues through constitutional lens rather than policy effectiveness* |
| Root Cause Agreement | 5/10 | *Agree that congressional intent matters but may disagree about what the original intent of Bayh-Dole was* |

**Source references:**

- *Mossoff, Adam. "Rethinking the Development of Patents: An Intellectual History." Hastings Law Journal, 2001*
- *Rai, Arti K. "Regulating Scientific Research: Intellectual Property Rights and the Norms of Science." Northwestern University Law Review, 1999*

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| *Activate march-in rights* | 5/10 | *"March-in is a valid exercise of congressional authority if consistent with original statutory intent"* | *Focused on statutory interpretation rather than policy outcome* |
| *Strengthen Bayh-Dole accountability* | 5/10 | *"Congress has authority to impose conditions on patent grants; the question is whether these are wise"* | *Accepts constitutional authority; evaluates policy prudentially* |
| *Reform TTO incentives* | 4/10 | *"Federal regulation of university operations raises federalism concerns"* | *States' rights concerns about federal mandates on state universities* |
| *Bridge the valley of death* | 5/10 | *"Spending Clause authorizes such programs; question is whether they are prudent"* | *No constitutional objection; policy judgment varies* |
| *Modernize lab tech transfer* | 6/10 | *"Government has authority and responsibility to manage its property effectively"* | *Supports efficient government management within constitutional bounds* |
| *Strengthen SBIR/STTR* | 5/10 | *"Programs are within congressional authority; reforms should respect statutory framework"* | *No constitutional objection; evaluates on prudential grounds* |
| *Ensure public return on drugs* | 4/10 | *"Government use authority exists but must be exercised within constitutional limits"* | *Accepts authority but concerned about due process and takings implications* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| *Publicly Funded Research Accountability Act* | 5/10 | *"Constitutionally permissible exercise of congressional power, with some due process concerns in march-in procedures"* | *Focused on constitutional mechanics rather than policy goals* |
| *Innovation Commercialization and Regional Equity Act* | 5/10 | *"Within congressional spending and commerce authority; federalism concerns about state university mandates"* | *Accepts federal authority for federal programs; cautious about extending to state institutions* |

#### Alternative Proposals

- Ensure that any march-in exercise provides robust due process protections
- Ground reforms in the Patent Clause's stated purpose of promoting "the Progress of Science and useful Arts"
- Respect state sovereignty over public university governance while setting conditions on federal funding
- Ensure that reporting requirements are proportionate to the government interest served

#### Coalition Potential

- **Natural allies:** Conservative (on limited government), Centrist (on procedural fairness)
- **Potential bridges:** Liberal (on constitutional basis for reform), Populist (on accountability)
- **Unlikely partners:** Progressive, Democratic Socialist (if reform is perceived as exceeding constitutional bounds)

---

### Populist Perspective

#### Engagement Consistency Assessment

**Score: 3/5 - Mixed Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | *Genuine anti-elite sentiment drives populist positions on technology transfer; anger at pharmaceutical pricing is authentic* |
| Principle consistency | *Anti-corporate rhetoric is strong but can conflict with pro-business instincts depending on the specific industry and context* |
| Goalpost stability | *Moderate; positions can shift based on which elites are being targeted and whether reform is framed as anti-business or anti-bureaucracy* |
| Zero-sum behavior | *Moderate; tends to frame issues as "the people vs. the elite" which can impede nuanced policy discussion* |

**Justification:** Populists have strong and genuine anger about pharmaceutical companies profiting from publicly funded research, but their broader policy framework is less consistent. They may oppose government-granted monopolies for Big Pharma while supporting similar protections for other industries.

**Evidence for assessment:**

- *Bipartisan populist support for drug pricing reform (e.g., Trump-era drug importation proposals, Sanders drug pricing bills)*
- *Populist members of Congress from both parties criticizing pharmaceutical pricing*
- *Right-wing populist support for anti-monopoly positions that conflict with traditional Republican deference to business*

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 7/10 | *Strong agreement that the system benefits elites at the expense of ordinary Americans; less engagement with technical details* |
| Root Cause Agreement | 6/10 | *Agree that corporate capture and elite self-dealing are root causes; may not engage with institutional analysis (TTO culture, etc.)* |

**Source references:**

- *American Compass. "The Real Problem with Drug Prices." Policy brief, 2023*
- *Populist rhetoric from both right and left on pharmaceutical pricing in Congressional Record*

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| *Activate march-in rights* | 7/10 | *"The government should stand up to Big Pharma on behalf of the people"* | *Anti-corporate sentiment; may not engage with implementation details* |
| *Strengthen Bayh-Dole accountability* | 6/10 | *"Make it transparent who is profiting from taxpayer research"* | *Supports transparency as anti-elite tool* |
| *Reform TTO incentives* | 4/10 | *"University bureaucrats are part of the problem"* | *Skepticism toward institutional reform that does not directly benefit working people* |
| *Bridge the valley of death* | 6/10 | *"Help American innovators and job creators, not Wall Street"* | *Supports if framed as helping small businesses and creating jobs* |
| *Modernize lab tech transfer* | 5/10 | *"Cut the red tape, but keep the benefits in America"* | *Supports efficiency but insists on domestic manufacturing* |
| *Strengthen SBIR/STTR* | 7/10 | *"Support small businesses, not repeat winners gaming the system"* | *Strong support for anti-fraud and anti-concentration reforms* |
| *Ensure public return on drugs* | 8/10 | *"Taxpayers funded it, taxpayers should afford it"* | *Core populist demand; drug pricing is a mobilizing issue* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| *Publicly Funded Research Accountability Act* | 7/10 | *"Good -- hold Big Pharma accountable for profiting from taxpayer research"* | *Strong support for pricing and transparency provisions* |
| *Innovation Commercialization and Regional Equity Act* | 7/10 | *"Bring innovation to overlooked communities, not just the coasts"* | *Strong support for regional equity; may want stronger domestic manufacturing requirements* |

#### Alternative Proposals

- Require domestic manufacturing for all products developed from publicly funded research
- Create "Buy American" provisions for technology transfer licensing
- Impose windfall profit taxes on companies that price publicly funded inventions above specified thresholds
- Direct more SBIR/STTR funding to rural and post-industrial regions

#### Coalition Potential

- **Natural allies:** Progressive, Democratic Socialist (on drug pricing and anti-corporate measures)
- **Potential bridges:** Conservative (on domestic manufacturing), Liberal (on pricing reform)
- **Unlikely partners:** Libertarian (on government intervention in markets)

---

### Centrist Perspective

#### Engagement Consistency Assessment

**Score: 4/5 - Mostly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | *Genuine commitment to evidence-based, pragmatic reform; positions reflect stated values* |
| Principle consistency | *Consistent application of "what works" framework, though this can lead to incremental positions that avoid fundamental questions* |
| Goalpost stability | *Stable; centrists have maintained consistent support for bipartisan innovation policy* |
| Zero-sum behavior | *Very low; centrists are the most willing to seek compromise across perspectives* |

**Justification:** Centrists approach technology transfer with a pragmatic, evidence-based framework that produces consistent positions. Their commitment to compromise makes them reliable coalition partners, though their aversion to controversial positions can limit the ambition of reforms they support.

**Evidence for assessment:**

- *Bipartisan Policy Center analyses of technology transfer reform*
- *Centrist members of Congress supporting CHIPS and Science Act provisions on tech transfer*
- *Information Technology and Innovation Foundation (ITIF) producing balanced analyses that draw from both sides*

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 7/10 | *Agree with factual analysis; somewhat more optimistic about the system's performance than the project analysis suggests* |
| Root Cause Agreement | 6/10 | *Agree with most structural analysis but may attribute more to complexity and less to industry capture than the project analysis does* |

**Source references:**

- *ITIF. "University Technology Transfer: Current Challenges and Future Directions." Policy report, 2023*
- *Bipartisan Policy Center. "Innovation for All: Building Regional Innovation Ecosystems." Report, 2022*

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| *Activate march-in rights* | 5/10 | *"Should be available but used judiciously; a clear framework is needed"* | *Supports the principle but wary of overuse that could disrupt innovation* |
| *Strengthen Bayh-Dole accountability* | 7/10 | *"Transparency and reporting are reasonable and overdue"* | *Strong support for accountability without radical restructuring* |
| *Reform TTO incentives* | 7/10 | *"Impact-based metrics are better than revenue-only metrics"* | *Supports evidence-based improvement of institutional practices* |
| *Bridge the valley of death* | 8/10 | *"The Translational Fund addresses a well-documented market failure"* | *Strongest support; addresses a problem both sides acknowledge* |
| *Modernize lab tech transfer* | 8/10 | *"Streamlining lab partnerships is an obvious improvement"* | *Near-universal support for reducing bureaucratic barriers* |
| *Strengthen SBIR/STTR* | 7/10 | *"Incremental reforms to a successful program are appropriate"* | *Supports targeted improvements without radical restructuring* |
| *Ensure public return on drugs* | 5/10 | *"Important goal but must be balanced against innovation incentives"* | *Seeks middle ground that addresses pricing without discouraging R&D* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| *Publicly Funded Research Accountability Act* | 6/10 | *"Good on transparency; march-in provisions may need more safeguards"* | *Supports accountability but wants more procedural protections for patent holders* |
| *Innovation Commercialization and Regional Equity Act* | 8/10 | *"Strong bipartisan potential; addresses real gaps in the innovation ecosystem"* | *The most politically viable of the proposals; strong support* |

#### Alternative Proposals

- Establish an independent Technology Transfer Commission to evaluate and recommend reforms on an ongoing basis
- Create a voluntary "Public Benefit License" framework that universities can opt into for favorable federal treatment
- Develop a phased approach to march-in that begins with negotiation and escalates to compulsory licensing only as a last resort
- Fund pilot programs to test reform ideas before scaling

#### Coalition Potential

- **Natural allies:** Liberal (on evidence-based reform), Conservative (on commercialization efficiency)
- **Potential bridges:** All perspectives on specific, narrowly tailored reforms
- **Unlikely partners:** None categorically; centrists seek to build the broadest possible coalition

---

### Religious Right Perspective

#### Engagement Consistency Assessment

**Score: 3/5 - Mixed Consistency**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | *Technology transfer is not a priority issue; positions largely follow conservative coalition partners* |
| Principle consistency | *Faith-based concern for the vulnerable (access to medicines) can conflict with free-market and pro-business coalition positions* |
| Goalpost stability | *Low engagement means positions are not well-developed and may shift based on framing* |
| Zero-sum behavior | *Low; this is not a culturally salient issue for the Religious Right* |

**Justification:** The Religious Right does not have a developed position on technology transfer policy. Positions tend to follow conservative coalition partners (pro-business, anti-regulation) but can shift when the issue is framed in terms of access to medicines for vulnerable populations, which resonates with faith-based values of compassion and stewardship.

**Evidence for assessment:**

- *Limited Religious Right engagement on technology transfer or Bayh-Dole policy specifically*
- *Faith-based organizations supporting access to medicines in global health contexts (e.g., PEPFAR)*
- *Evangelical leaders expressing concern about pharmaceutical pricing in health care access debates*

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 5/10 | *Limited engagement; generally defers to conservative analysis but may be moved by access concerns* |
| Root Cause Agreement | 4/10 | *Tends to accept conservative framing that the system works well; not deeply engaged with structural analysis* |

**Source references:**

- *National Association of Evangelicals. Statements on healthcare access and pharmaceutical pricing. Various dates*
- *Religious Right positions on technology transfer are largely inferred from broader conservative coalition positions*

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| *Activate march-in rights* | 4/10 | *"Government should respect property rights, but access to medicines matters"* | *Tension between conservative alliance and faith-based compassion* |
| *Strengthen Bayh-Dole accountability* | 4/10 | *"Accountability is good but regulation can burden institutions"* | *Follows conservative position but not deeply held* |
| *Reform TTO incentives* | 5/10 | *"If it helps research universities including faith-based institutions, it could be good"* | *Interested in ensuring religious institutions benefit* |
| *Bridge the valley of death* | 5/10 | *"Innovation serves human flourishing"* | *Supportive of innovation in general; no strong position on specific programs* |
| *Modernize lab tech transfer* | 5/10 | *"Efficiency in government is always good"* | *Generic support for reducing waste* |
| *Strengthen SBIR/STTR* | 5/10 | *"Small business support is generally positive"* | *Follows conservative support for business programs* |
| *Ensure public return on drugs* | 4/10 | *"The poor should have access to medicines, but price controls are problematic"* | *Genuine compassion tension with free-market ideology* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| *Publicly Funded Research Accountability Act* | 4/10 | *"Some good provisions on transparency, but pricing provisions go too far"* | *Follows conservative position with some sympathy for access concerns* |
| *Innovation Commercialization and Regional Equity Act* | 5/10 | *"Bringing innovation to rural and overlooked communities is positive"* | *Supports geographic equity framing; resonates with concern for overlooked communities* |

#### Alternative Proposals

- Ensure that technology transfer policies support faith-based universities and research institutions
- Frame access to medicines as a moral imperative alongside economic efficiency
- Support voluntary industry commitments to patient access programs grounded in corporate social responsibility
- Advocate for international technology transfer to support global health missions

#### Coalition Potential

- **Natural allies:** Conservative (general coalition alignment)
- **Potential bridges:** Liberal (on access to medicines as moral imperative), Populist (on helping overlooked communities)
- **Unlikely partners:** Progressive, Democratic Socialist (coalition alignment prevents open engagement)

---

### Democratic Socialist Perspective

#### Engagement Consistency Assessment

**Score: 5/5 - Highly Consistent**

| Indicator | Assessment |
|-----------|------------|
| Stated vs actual motivations | *Completely aligned: publicly funded research should yield public benefit; private capture of public goods is unjust* |
| Principle consistency | *Highest consistency; the public-investment-yields-public-benefit principle is applied uniformly and without exception* |
| Goalpost stability | *Very stable; demands have been consistent for decades and are grounded in a coherent political philosophy* |
| Zero-sum behavior | *Moderate; may frame reform as insufficient and demand more transformative changes that are politically unattainable* |

**Justification:** Democratic Socialists have the most internally consistent position on technology transfer: public investment should produce public goods, not private profits. This consistency makes their positions highly predictable, though their maximum demands may exceed what is politically achievable, potentially complicating coalition formation.

**Evidence for assessment:**

- *Senator Sanders introducing Prescription Drug Price Relief Act and related legislation repeatedly*
- *Democratic Socialists of America platform on pharmaceutical pricing and public ownership*
- *Academic democratic socialist scholarship on the commons, public goods, and knowledge governance*

#### Position Scores

| Dimension | Score | Reasoning |
|-----------|-------|-----------|
| Current State Assessment | 9/10 | *Strong agreement with the analysis, with emphasis on systemic injustice of private capture of public research* |
| Root Cause Agreement | 10/10 | *Full agreement with structural analysis; would emphasize capitalism and intellectual property as root causes even more strongly* |

**Source references:**

- *Dean Baker. "Rigged: How Globalization and the Rules of the Modern Economy Are Structured to Make the Rich Richer." Center for Economic and Policy Research, 2016*
- *Democratic Socialists of America. "A Vision for Public Pharma." Policy document, 2022*

#### Solution Evaluations

| Solution | Score | Stated Position | Underlying Concerns |
|----------|-------|-----------------|---------------------|
| *Activate march-in rights* | 9/10 | *"March-in should be exercised immediately and aggressively"* | *Viewed as a minimum necessary step, not an end goal* |
| *Strengthen Bayh-Dole accountability* | 7/10 | *"Helpful but does not address the fundamental problem of privatizing public knowledge"* | *Supports as incremental step; wants systemic change* |
| *Reform TTO incentives* | 6/10 | *"TTOs should be reformed but the real issue is the IP system itself"* | *Sees TTO reform as treating symptoms rather than causes* |
| *Bridge the valley of death* | 6/10 | *"Public investment is good but should come with public ownership, not just public subsidy"* | *Wants public equity stakes and public enterprise, not just grants to private firms* |
| *Modernize lab tech transfer* | 5/10 | *"Labs should serve the public directly, not funnel technology to corporations"* | *Prefers public enterprise over private licensing* |
| *Strengthen SBIR/STTR* | 5/10 | *"Small business subsidies are less effective than public enterprise"* | *Prefers public research and manufacturing over subsidies to private firms* |
| *Ensure public return on drugs* | 10/10 | *"The public funded it, the public should own it"* | *Core demand; willing to support this legislation as a step toward broader goals* |

#### Legislation Evaluations

| Bill | Score | Stated Position | Underlying Concerns |
|------|-------|-----------------|---------------------|
| *Publicly Funded Research Accountability Act* | 7/10 | *"A necessary step, but does not go far enough toward public ownership of publicly funded inventions"* | *Supports as incremental reform; would push for stronger provisions* |
| *Innovation Commercialization and Regional Equity Act* | 6/10 | *"Regional equity is important, but the fund should support public enterprise, not just private commercialization"* | *Wants public ownership elements added* |

#### Alternative Proposals

- Establish a publicly owned pharmaceutical manufacturer for drugs developed from public research
- Default to public ownership (not just a government license) for inventions developed with majority public funding
- Create a Public Innovation Fund that takes equity stakes in startups commercializing public research and returns profits to the public
- Shorten patent terms and expand compulsory licensing provisions
- Transition from Bayh-Dole's institutional ownership model to a public commons model for publicly funded knowledge

#### Coalition Potential

- **Natural allies:** Progressive (on public ownership and pricing), Liberal (on access and accountability)
- **Potential bridges:** Populist (on anti-corporate measures and drug pricing)
- **Unlikely partners:** Conservative, Libertarian, Religious Right (fundamental disagreement on ownership and markets)

---

## Summary Tables

### Master Comparison

| Perspective | Consistency | Current State | Root Causes | Solutions Avg | Legislation Avg |
|-------------|-------------|---------------|-------------|---------------|-----------------|
| Conservative | 3/5 | 5/10 | 4/10 | 4.4/10 | 3.5/10 |
| Liberal | 4/5 | 8/10 | 7/10 | 7.7/10 | 8.0/10 |
| Progressive | 4/5 | 9/10 | 9/10 | 7.7/10 | 7.0/10 |
| Libertarian | 3/5 | 5/10 | 4/10 | 3.3/10 | 2.5/10 |
| Constitutionalist | 4/5 | 5/10 | 5/10 | 4.9/10 | 5.0/10 |
| Populist | 3/5 | 7/10 | 6/10 | 6.1/10 | 7.0/10 |
| Centrist | 4/5 | 7/10 | 6/10 | 6.7/10 | 7.0/10 |
| Religious Right | 3/5 | 5/10 | 4/10 | 4.6/10 | 4.5/10 |
| Democratic Socialist | 5/5 | 9/10 | 10/10 | 6.9/10 | 6.5/10 |

### Solution Support Matrix

| Solution | Con | Lib | Prog | Libt | Const | Pop | Cent | RelR | DemSoc |
|----------|-----|-----|------|------|-------|-----|------|------|--------|
| *Activate march-in rights* | 2 | 8 | 9 | 3 | 5 | 7 | 5 | 4 | 9 |
| *Strengthen Bayh-Dole accountability* | 3 | 8 | 8 | 3 | 5 | 6 | 7 | 4 | 7 |
| *Reform TTO incentives* | 5 | 7 | 7 | 4 | 4 | 4 | 7 | 5 | 6 |
| *Bridge the valley of death* | 6 | 8 | 7 | 3 | 5 | 6 | 8 | 5 | 6 |
| *Modernize lab tech transfer* | 7 | 7 | 6 | 5 | 6 | 5 | 8 | 5 | 5 |
| *Strengthen SBIR/STTR* | 6 | 8 | 7 | 3 | 5 | 7 | 7 | 5 | 5 |
| *Ensure public return on drugs* | 2 | 8 | 10 | 2 | 4 | 8 | 5 | 4 | 10 |

### Legislation Support Matrix

| Bill | Con | Lib | Prog | Libt | Const | Pop | Cent | RelR | DemSoc |
|------|-----|-----|------|------|-------|-----|------|------|--------|
| *Publicly Funded Research Accountability Act* | 2 | 8 | 7 | 2 | 5 | 7 | 6 | 4 | 7 |
| *Innovation Commercialization and Regional Equity Act* | 5 | 8 | 7 | 3 | 5 | 7 | 8 | 5 | 6 |

### Engagement Consistency Distribution

| Level | Count | Perspectives |
|-------|-------|--------------|
| 5 - Highly Consistent | 1 | *Democratic Socialist* |
| 4 - Mostly Consistent | 4 | *Liberal, Progressive, Constitutionalist, Centrist* |
| 3 - Mixed Consistency | 4 | *Conservative, Libertarian, Populist, Religious Right* |
| 2 - Low Consistency | 0 | *None* |
| 1 - Unpredictable | 0 | *None* |

**High Consistency Majority:** 5/9 perspectives rated 4 or above

### Common Ground Synthesis

This matrix identifies which reforms have potential cross-ideological support and which face structural opposition.

| Reform Category | Broad Support (5+) | Narrow Support (3-4) | Structural Opposition |
|-----------------|-------------------|---------------------|----------------------|
| *Modernize lab tech transfer* | *Conservative, Liberal, Progressive, Constitutionalist, Populist, Centrist, Religious Right* | *Libertarian, Democratic Socialist* | *None* |
| *Bridge the valley of death* | *Conservative, Liberal, Progressive, Constitutionalist, Populist, Centrist, Religious Right, Democratic Socialist* | *None* | *Libertarian* |
| *Strengthen SBIR/STTR* | *Conservative, Liberal, Progressive, Constitutionalist, Populist, Centrist, Religious Right* | *Libertarian, Democratic Socialist* | *None* |
| *Strengthen Bayh-Dole accountability* | *Liberal, Progressive, Constitutionalist, Populist, Centrist, Democratic Socialist* | *Conservative, Libertarian, Religious Right* | *None* |
| *Reform TTO incentives* | *Conservative, Liberal, Progressive, Centrist, Religious Right, Democratic Socialist* | *Libertarian, Constitutionalist, Populist* | *None* |
| *Activate march-in rights* | *Liberal, Progressive, Constitutionalist, Populist, Centrist, Democratic Socialist* | *Conservative, Libertarian, Religious Right* | *None (but 3 perspectives score 2-4)* |
| *Ensure public return on drugs* | *Liberal, Progressive, Populist, Democratic Socialist* | *Centrist, Constitutionalist, Religious Right* | *Conservative, Libertarian* |

**Key insight:** Lab modernization, valley of death bridging, and SBIR/STTR reform enjoy the broadest support across ideological lines. March-in rights and drug pricing reforms are deeply polarizing but have majority support. The most viable strategy is to lead with broadly supported reforms while building momentum for the more contested but higher-impact proposals.

---

## Compromise Proposals

### Compromise 1: *The Innovation Accountability and Commercialization Compact*

**Bridges:** *Conservative + Liberal + Centrist + Populist + Constitutionalist*

**Core Agreement:** *All five perspectives agree that publicly funded research should be commercialized effectively and that the current system has gaps in both commercialization and accountability. They differ on the role of pricing provisions but share interest in transparency and efficient commercialization.*

**Policy Description:**

A combined approach that pairs new commercialization investment with accountability reforms:

- Create the Translational Research and Commercialization Fund ($1 billion annually) to bridge the valley of death
- Establish a public database of federally funded inventions, licenses, and commercial outcomes
- Implement a graduated march-in framework: (1) notification to licensee of concerns, (2) negotiation period, (3) formal determination, (4) march-in as last resort -- with price among the factors evaluated but not the sole factor
- Streamline national lab partnerships with 90-day approval timelines
- Reform SBIR/STTR with anti-fraud measures and geographic equity outreach

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Conservative | *Commercialization investment benefits business; graduated march-in avoids sudden government action; transparency reduces need for regulation* |
| Liberal | *Public database enables accountability; graduated march-in creates real enforcement pathway; equity provisions address geographic disparity* |
| Centrist | *Evidence-based, bipartisan approach; pilot-testable; avoids politically extreme positions* |
| Populist | *Transparency exposes corporate profiteering; regional equity brings innovation to overlooked communities; anti-fraud measures protect taxpayers* |
| Constitutionalist | *Graduated process satisfies due process; within clear congressional authority; respects federalism* |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Conservative | *Acceptance of march-in as a viable tool, including price as one factor (not sole factor)* |
| Liberal | *Acceptance of graduated rather than immediate march-in; price as one factor rather than the primary trigger* |
| Centrist | *Commitment to a specific march-in framework rather than indefinite study* |
| Populist | *Acceptance of nuanced multi-factor approach rather than simple "if overpriced, march in" rule* |
| Constitutionalist | *Acceptance of federal reporting mandates on state university TTOs receiving federal funds* |

**Viability Assessment:**

- **Coalition Size:** 5/9 perspectives
- **High Consistency Ratio:** 3/5 coalition members rated 4+ consistency (Liberal, Centrist, Constitutionalist)
- **Durability:** *Moderate to high. The combining of popular commercialization programs with accountability reform creates political difficulty in opposing one without rejecting the other*
- **Implementation Path:** *Could be introduced as an amendment to COMPETES/CHIPS reauthorization; commercialization elements attract bipartisan support that carries accountability provisions*

---

### Compromise 2: *Regional Innovation Equity Initiative*

**Bridges:** *Conservative + Liberal + Populist + Centrist + Religious Right + Progressive*

**Core Agreement:** *Broad agreement that innovation benefits are too geographically concentrated, leaving many communities without access to the economic opportunities created by federal research investment. All perspectives support some form of geographic diversification, though they differ on mechanisms.*

**Policy Description:**

A focused initiative to spread innovation infrastructure across the country:

- Scale NSF Regional Innovation Engines and EDA Tech Hubs with $2 billion in multi-year funding
- Create state SBIR/STTR matching programs with federal incentives
- Expand Lab-Embedded Entrepreneurship Programs to all national labs
- Fund innovation infrastructure (incubators, accelerators, shared labs) in underserved regions
- Establish technical assistance centers for SBIR/STTR applicants in low-participation states
- Require that at least 25% of SBIR Phase I awards go to first-time applicants

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Conservative | *Creates economic opportunity through market mechanisms; reduces dependence on government by building self-sustaining ecosystems* |
| Liberal | *Addresses geographic and demographic inequality in innovation access* |
| Populist | *Brings innovation to overlooked communities; reduces coastal elite concentration* |
| Centrist | *Evidence-based approach with measurable outcomes; builds on proven programs* |
| Religious Right | *Supports rural and faith-community regions; creates economic opportunity in overlooked areas* |
| Progressive | *Begins to address structural inequality in the innovation economy* |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Conservative | *Acceptance of geographic equity mandates as legitimate policy tool* |
| Liberal | *Acceptance that regional programs alone do not address systemic pricing and access issues* |
| Populist | *Acceptance of merit-based selection criteria alongside geographic targets* |
| Centrist | *Commitment to specific geographic equity targets rather than purely merit-based distribution* |
| Religious Right | *Active engagement with innovation policy that is outside traditional issue set* |
| Progressive | *Acceptance of incremental geographic reform without systemic restructuring* |

**Viability Assessment:**

- **Coalition Size:** 6/9 perspectives
- **High Consistency Ratio:** 3/6 coalition members rated 4+ consistency (Liberal, Centrist, Progressive)
- **Durability:** *High. Geographic equity has bipartisan appeal and creates geographically distributed constituencies for continued investment*
- **Implementation Path:** *Could be enacted through appropriations process; builds on existing CHIPS and Science Act authorizations*

---

### Compromise 3: *Pharmaceutical Transparency and Graduated Accountability*

**Bridges:** *Liberal + Progressive + Populist + Democratic Socialist + Centrist*

**Core Agreement:** *All five perspectives agree that the public deserves transparency about the taxpayer contribution to drug development and that some form of accountability for pricing is appropriate when public investment is substantial.*

**Policy Description:**

A transparency-first approach to pharmaceutical pricing accountability:

- Require FDA applicants to disclose all federal funding behind each drug at approval
- Publish a public "taxpayer contribution report" for each approved drug
- Establish a graduated accountability framework:
    - For drugs with majority public funding: automatic review of pricing relative to international benchmarks
    - For drugs with pricing above 3x median international price: mandatory negotiation between the government and the manufacturer
    - For drugs where negotiation fails: authority to exercise march-in or government-use license as a last resort
- Create a standing Pharmaceutical Pricing Review Board to oversee the process

**Concern Mapping:**

| Perspective | How This Addresses Their Concerns |
|-------------|-----------------------------------|
| Liberal | *Creates meaningful accountability pathway; transparency enables public scrutiny* |
| Progressive | *Establishes principle that public funding creates public obligations; provides enforcement mechanism* |
| Populist | *Exposes corporate profiteering from taxpayer research; creates leverage for price negotiation* |
| Democratic Socialist | *Steps toward public control of publicly funded goods; creates framework that can be strengthened over time* |
| Centrist | *Graduated approach avoids extreme measures; evidence-based criteria; negotiation before compulsion* |

**Concessions:**

| Perspective | What They Give Up |
|-------------|-------------------|
| Liberal | *Acceptance of graduated process rather than immediate pricing provisions* |
| Progressive | *Acceptance of negotiation before march-in rather than immediate exercise* |
| Populist | *Acceptance of expert review board rather than simple legislative mandate* |
| Democratic Socialist | *Acceptance of reform within the existing IP framework rather than systemic restructuring* |
| Centrist | *Commitment to specific march-in triggers rather than indefinite discretion* |

**Viability Assessment:**

- **Coalition Size:** 5/9 perspectives
- **High Consistency Ratio:** 4/5 coalition members rated 4+ consistency (Liberal, Progressive, Centrist, Democratic Socialist)
- **Durability:** *Moderate. Strong on left-center coalition; vulnerable to pharmaceutical industry counter-mobilization. High consistency ratio suggests the coalition would hold under pressure*
- **Implementation Path:** *Would require standalone legislation; significant industry opposition but growing public pressure on drug pricing creates political opening*

---

## Strategic Implications

### Most Viable Coalition

The most viable initial coalition combines Liberals, Centrists, Populists, and Constitutionalists around Compromise 1 (the Innovation Accountability and Commercialization Compact). This coalition has:

- Sufficient political breadth to attract bipartisan support in Congress
- A mixture of popular commercialization programs and accountability reforms that are difficult to oppose separately
- High engagement consistency among key members (Liberal 4/5, Centrist 4/5, Constitutionalist 4/5)
- A policy package that can be attached to must-pass legislation (COMPETES reauthorization, appropriations)

### Key Obstacles

- **Pharmaceutical industry lobbying**: The single greatest obstacle to any reform involving pricing or march-in. The industry's financial resources, political access, and narrative-setting capacity far exceed those of reform advocates
- **University inertia**: Major research universities benefit from the status quo and have significant lobbying capacity through AAU, APLU, and AUTM
- **Issue salience**: Technology transfer is a low-salience issue for most voters, giving organized opposition disproportionate influence
- **Congressional gridlock**: Ambitious legislative reforms face the general challenge of moving legislation through a polarized Congress

### Low Consistency Partners

Conservative (3/5), Libertarian (3/5), Populist (3/5), and Religious Right (3/5) are the least consistent perspectives on this issue:

- **Conservative**: Engage through commercialization and deregulatory elements; avoid framing reforms as anti-business
- **Libertarian**: Highlight the anti-monopoly aspects of reform; frame march-in as correcting a government distortion rather than imposing new government control
- **Populist**: Frame reforms as standing up for taxpayers against corporate elites; regional equity provisions are a powerful engagement tool
- **Religious Right**: Frame access to medicines as a moral imperative; engage through faith-based organizations that work on healthcare access

### Recommended Approach

1. **Lead with Compromise 2** (Regional Innovation Equity): the broadest coalition (6/9), the least opposition, and strong bipartisan appeal. Success here builds momentum and trust
2. **Follow with Compromise 1** (Innovation Accountability and Commercialization Compact): pairs popular commercialization investment with accountability reforms, making it politically difficult to oppose
3. **Build toward Compromise 3** (Pharmaceutical Transparency and Graduated Accountability): the most impactful but most politically challenging reform. Build the evidence base, public awareness, and political will through the transparency provisions before escalating to pricing accountability
4. **Throughout**: continue filing march-in petitions, generating public comment, and building the record that strengthens the case for eventual exercise of march-in authority

---

## Document Navigation

- Previous: [Legislation](11-legislation.md)
- Up: [Science](../01-overview.md)
